Takeda announces voluntary withdrawal of lung cancer therapy
Send a link to a friend
[October 03, 2023]
(Reuters) -Japan's Takeda Pharmaceutical said on Monday it will
voluntarily withdraw its lung cancer therapy from the United States,
where it had received an accelerated approval in 2021, after it failed
to meet the main goal in a late-stage study.
U.S.-listed shares of the company fell about 6% to $14.39 in extended
trading as the failed study meant the therapy did not fulfill the
confirmatory data requirements of the U.S. Food and Drug
Administration's accelerated approval nor the conditional marketing
approvals granted in other countries.
In July, Takeda had said the study had been halted due to futility as it
was unlikely to meet its goal. It also withdrew its application for
marketing authorization in the European Union in 2022.
The late-stage trial studied the safety and efficacy of Takeda's
Exkivity as a monotherapy versus a type of chemotherapy in patients with
non-small cell lung cancer (NSCLC).
Full data from the late-stage trial will be presented at an upcoming
medical meeting or published in a peer-review journal, the company said.
Takeda also intends to initiate voluntary withdrawal globally where the
therapy was approved and is working with regulators in other countries
where it was available on the next steps.
![](http://archives.lincolndailynews.com/2023/Oct/03/images/ads/current/culligan_sda_FOOTBALL_2023.png)
[to top of second column]
|
![](../images/100323PIX/health22.jpg)
Takeda Pharmaceutical Co's logo is seen at its new headquarters in
Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon/File Photo
![](http://archives.lincolndailynews.com/2023/Oct/03/images/ads/current/atlantabank_quarter_FAIR_2023.png) The therapy was approved in
Switzerland, South Korea, Australia and China, besides the United
States.
The U.S. FDA had approved Exkivity for NSCLC patients with a
specific gene mutation called EGFR Exon20 insertions whose disease
had progressed on or after chemotherapy, based on results from an
early- to mid-stage trial.
Johnson & Johnson is expecting its combination therapy of antibody
treatment Rybrevant and experimental drug lazertinib to become a
first-line treatment for NSCLC patients with the mutation.
Takeda said on Monday it will continue to assess the impact of the
withdrawal and update its annual forecast for the fiscal year ending
March 31, 2024.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
and Shinjini Ganguli)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |